Trials / Recruiting
RecruitingNCT06566586
A Clinical Study to Evaluate the Efficacy and Safety of TQB3702 Tablets Combined With Immunochemotherapy for the Treatment of B-cell Lymphoma
A Phase II Clinical Trial to Evaluate the Efficacy and Safety of TQB3702 Tablets Combined With Immunochemotherapy for the Treatment of B-cell Lymphoma
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 80 (estimated)
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the efficacy and safety of TQB3702 tablets combined with immunochemotherapy for the treatment of B-cell lymphoma
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TQB3702 tablets+Chemotherapy regimen | TQB3702 tablets: Tyrosine kinase inhibitor； Chemotherapy regimen：inhibiting tumor cell proliferation, suppressing DNA synthesis, inducing cell apoptosis, enhancing immune system function, and inhibiting angiogenesis； |
Timeline
- Start date
- 2024-11-06
- Primary completion
- 2026-03-01
- Completion
- 2027-12-01
- First posted
- 2024-08-22
- Last updated
- 2024-11-20
Locations
30 sites across 1 country: China
Source: ClinicalTrials.gov record NCT06566586. Inclusion in this directory is not an endorsement.